Interference With VIP to Distinguish Between Real and False VIPoma: National Study From the French Endocrine Tumors Group.

analytic interference neuroendocrine tumor vasoactive intestinal peptide

Journal

Journal of the Endocrine Society
ISSN: 2472-1972
Titre abrégé: J Endocr Soc
Pays: United States
ID NLM: 101697997

Informations de publication

Date de publication:
23 May 2024
Historique:
received: 05 09 2023
medline: 10 6 2024
pubmed: 10 6 2024
entrez: 10 6 2024
Statut: epublish

Résumé

Vasoactive intestinal peptide (VIP)-secreting tumors (VIPomas) are digestive neuroendocrine tumors in which the hormonal secretion is life-threatening. Biological confirmation is obtained by demonstrating an elevation in plasma VIP, usually using radioimmunoassay (RIA). In some cases, analytical interference is suspected. We developed 3 different techniques to detect interference in VIP RIA. Three techniques were used: RIA after Sephadex column chromatography separation, RIA after polyethylene glycol precipitation, and A total of 15 patients with FPV elevation and 9 RV patients were included. Interference was detected in all FPV patients vs none in RV. Clinical and biochemical parameters did not differ between FPV and RV patients, but VIP concentration in RIA was significantly higher in FPV patients than in RV patients (228 pmol/L vs 66 pmol/L, We developed 3 different laboratory techniques to reveal interference in RIA VIP assays. The diagnostic performance of all 3 was excellent. These techniques must be employed in cases of discordance between VIP elevation and clinical presentation.

Sections du résumé

Background UNASSIGNED
Vasoactive intestinal peptide (VIP)-secreting tumors (VIPomas) are digestive neuroendocrine tumors in which the hormonal secretion is life-threatening. Biological confirmation is obtained by demonstrating an elevation in plasma VIP, usually using radioimmunoassay (RIA). In some cases, analytical interference is suspected. We developed 3 different techniques to detect interference in VIP RIA.
Methods UNASSIGNED
Three techniques were used: RIA after Sephadex column chromatography separation, RIA after polyethylene glycol precipitation, and
Results UNASSIGNED
A total of 15 patients with FPV elevation and 9 RV patients were included. Interference was detected in all FPV patients vs none in RV. Clinical and biochemical parameters did not differ between FPV and RV patients, but VIP concentration in RIA was significantly higher in FPV patients than in RV patients (228 pmol/L vs 66 pmol/L,
Conclusion UNASSIGNED
We developed 3 different laboratory techniques to reveal interference in RIA VIP assays. The diagnostic performance of all 3 was excellent. These techniques must be employed in cases of discordance between VIP elevation and clinical presentation.

Identifiants

pubmed: 38854908
doi: 10.1210/jendso/bvae102
pii: bvae102
pmc: PMC11156571
doi:

Types de publication

Journal Article

Langues

eng

Pagination

bvae102

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society.

Auteurs

Benjamin Chevalier (B)

Department of Nuclear Medicine, Lille University Hospital, Lille 59000, France.
School of Medicine, University of Lille, Lille 59000, France.

Delphine Bonnet (D)

Department of Internal Medicine and Digestive Diseases, CHU Toulouse, Toulouse 31059, France.

Come Lepage (C)

Gastroenterology and Digestive Oncology, Hôpital Universitaire Le Bocage, Dijon 21079, France.

Marine Perrier (M)

Université Reims Champagne-Ardenne, Department of Gastroenterology and Digestive Oncology, Reims University Hospital, 51092 Reims, France.

Françoise Borson-Chazot (F)

Hospices Civils de Lyon, Hôpital Louis Pradel, Fédération d'Endocrinologie, Lyon 69500, France.

Juliette Abeillon (J)

Hospices Civils de Lyon, Hôpital Louis Pradel, Fédération d'Endocrinologie, Lyon 69500, France.

Jean Bernard Delobel (JB)

Hôpital Yves le Foll, Service de Gastroentérologie, Saint Brieuc 22000, France.

Arnaud Jannin (A)

School of Medicine, University of Lille, Lille 59000, France.
Department of Endocrinology, Diabetology and Metabolism, Lille University Hospital, Lille 59000, France.
CANTHER-Cancer-Heterogeneity Plasticity and Resistance to Therapies, University of Lille, UMR9020-U1277-CNRS, INSERM, CHU Lille, Lille 59000, France.

Julien Hadoux (J)

Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy Cancer Center, Villejuif 94800, France.

Magalie Haissaguere (M)

Endocrinology and Endocrine Oncology Department, Haut Leveque Hospital, University Hospital of Bordeaux, Bordeaux 33600, France.

Catherine Lombard-Bohas (C)

Hospices Civils de Lyon, Hôpital Edouard Herriot, Service d'Oncologie, Lyon 69003, France.

Thomas Walter (T)

Hospices Civils de Lyon, Hôpital Edouard Herriot, Service d'Oncologie, Lyon 69003, France.

Laurence Chardon (L)

Service de Biochimie, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron 69500, France.

Classifications MeSH